分析可溶性生长刺激因子2对AMI患者PCI术治疗后预后情况的影响

doi:10.3969/j.issn.1671-7171.2022.02.033

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1168 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To investigate the effect of soluble growth stimulating factor 2 (sST2) on the prognosis of patients with acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI). 【Methods】A total of 132 patients with AMI treated in our hospital from January 2019 to December 2020 was selected. According to the prognosis after PCI, they were divided into poor prognosis group (n=29) and good prognosis group (n=103). The clinical data of the two groups were compared, the levels of ST2 in patients with different Killip cardiac function grades were compared, the diagnostic value of ST2 in the diagnosis of poor prognosis after PCI in patients with AMI was analyzed, and the clinical factors affecting the poor prognosis were analyzed by COX risk regression model. 【Results】The time of chest pain and the levels of cTnI, ST2 and LDL-C in the poor prognosis group were higher than those in the good prognosis group, and LVEF was lower than those in the good prognosis group (P<0.05). The level of ST2 in Killip grade Ⅲ and Ⅳ patients was (28.04±7.52) ng/mL, which was significantly higher than that in Killip grade Ⅰ and Ⅱ (19.37±4.14) ng/mL(t=8.147, P<0.01). ROC curve evaluation of the value of ST2 in the diagnosis of poor prognosis in patients with AMI showed that the area under the diagnostic value curve (AUC) (95%CI) was 0.78 (0.67~0.88). COX risk regression model analysis showed that cTnI and ST2 were independent risk factors for poor prognosis in patients with AMI (P<0.05), and LVEF was a protective factor for poor prognosis in patients with AMI (P<0.05). 【Conclusion】ST2 is a potential clinical index to affect and evaluate the poor prognosis of AMI patients after PCI.

Key words： Myocardial Infarction/TH Acute Disease Percutaneous Coronary Intervention Somatomedins Prognosis

Received: 13 September 2021

PACS:

R542.22

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Rui
	ZENG Xin-chun

Cite this article:

WANG Rui,ZENG Xin-chun. Effect of Soluble Growth Stimulating Factor 2 on Prognosis of AMI Patients after PCI[J]. JOURNAL OF CLINICAL RESEARCH, 2022, 39(2): 278-280.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2022.02.033 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2022/V39/I2/278

[1] 李雪松,李彬,赵庭楷,等. 不同性别急性心肌梗死患者的临床特点及预后研究进展[J].中国心血管杂志,2018,23(6):519.
[2] KO S Q,VALSDOTTIR L R,STROM J B,et al. Meta-analysis of bleeding risk prediction scores in patients after percutaneous coronary intervention on dual antiplatelet therapy [J].Am J Cardiol,2018,122(11):1843-1852.
[3] 孟萌,魏佳丽,潘红,等. 血清HMGB1、sTLT-1水平对经皮冠状动脉介入治疗急性心肌梗死患者预后的影响[J].中国现代医学杂志,2019,29(24):38-43.
[4] 王江友.可溶性生长刺激表达因子-2对不同类型冠心病患者远期预后的影响[J].中国介入心脏病学杂志, 2016, 24(4): 195.
[5] 刘玲玲.ST2在急性冠脉综合征中的研究进展[J].中国心血管病研究, 2018, 16(6): 494-497.
[6] 张清. sST2、NT-proBNP、hs-cTnI水平评估心力衰竭预后及转归的临床价值[J].中西医结合心脑血管病杂志,2019,17(16):2501-2504.
[7] 毛雅晶.急性心肌梗死患者血浆 sST2水平与冠状动脉病变程度的相关性[J].中国动脉硬化杂志, 2012, 20(6): 557- 560.
[8] 李超,彭瑜,张钲.可溶性生长刺激表达基因2蛋白与急性心肌梗死的研究进展[J].中国循环杂志,2017,32(2):200-202.
[9] SÁNCHEZ-MÁS J,LAX A,ASENSIO-LÓPEZ M C,et al. Modulation of IL-33/ST2 system in postinfarction heart failure:correlation with cardiac remodelling markers [J].Euro J Clin Invest,2014,44(7):643-651.
[10] EGGERS K M, ARMSTRONG P W, CALIFF R M, et al. ST2 and mortality in non-ST-segment elevation acute coronary syndrome [J].Am Heart J,2010,159(5): 788-794.
[11] DEMYANETS S.Soluble ST2 and interleukin-33 levels in coronary artery disease: relation to disease activity and adverse outcome[J].PLoS One,2014,9(4): e95055.
[12] WANG T J, KAI C W, LARSON M G, et al. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study[J].Circulation,2012,126(13):1596.

[1]	. [J]. JOURNAL OF CLINICAL RESEARCH, 2022, 39(2): 284-286.